SEATTLE--(BUSINESS WIRE)--Jan. 7, 2004--Dendreon Corporation (Nasdaq:DNDN - News) today announced that it will present at the JP Morgan 22nd Annual Healthcare Conference taking place Jan. 12-15, 2004 at the Westin St. Francis Hotel in San Francisco.
Mitchell H. Gold, M.D., chief executive officer and president, will provide a corporate update on Tuesday, Jan. 13, 2004 at 4:00 p.m. PT. Dr. Gold’s presentation will be broadcast live and can be accessed by visiting Dendreon’s website www.dendreon.com under the “News & Events” section.
Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company’s lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial for the treatment of androgen independent prostate cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon’s product pipeline also includes monoclonal antibody, small molecule and prodrug product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to the uncertainty of Dendreon’s future access to capital, Dendreon’s limited operating history, risks associated with completing Dendreon’s clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the FDA will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon’s business, financial condition and results of operations, are contained in Dendreon’s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.
Contact:
Dendreon Corporation Julie Rathbun, 206-829-1500 (Communications/Investor Relations) pr@dendreon.com
Source: Dendreon Corporation
